Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,053 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Liu S, Zhou F, Liu Z, Xiong A, Jia Y, Zhao S, Zhao C, Li X, Jiang T, Han R, Qiao M, Liu Y, He Y, Li J, Li W, Gao G, Ren S, Su C, Zhou C. Liu S, et al. Among authors: zhou f, zhou c. Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066. doi: 10.21037/tlcr-19-396. Transl Lung Cancer Res. 2020. PMID: 32953484 Free PMC article.
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C, Zhou F, Shen J, Zhao J, O'Brien M. Su C, et al. Among authors: zhou f. Eur J Cancer. 2017 Sep;83:266-278. doi: 10.1016/j.ejca.2017.07.002. Epub 2017 Jul 29. Eur J Cancer. 2017. PMID: 28763691 Review.
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Jiang T, Li X, Wang J, Su C, Han W, Zhao C, Wu F, Gao G, Li W, Chen X, Li J, Zhou F, Zhao J, Cai W, Zhang H, Du B, Zhang J, Ren S, Zhou C, Yu H, Hirsch FR. Jiang T, et al. Among authors: zhou f, zhou c. Theranostics. 2017 Oct 17;7(19):4753-4762. doi: 10.7150/thno.21687. eCollection 2017. Theranostics. 2017. PMID: 29187901 Free PMC article. Clinical Trial.
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C, Li X, Zhang J, Su C, Chen X, Cai W, Gao G, Li W, Wu F, Li J, Zhao J, Hu Q, Zhao M, Zhou C, Hirsch FR. Liu S, et al. Among authors: zhou f, zhou c. Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4. Lung Cancer. 2018. PMID: 29748021
Lung cancer in never smokers-the East Asian experience.
Zhou F, Zhou C. Zhou F, et al. Among authors: zhou c. Transl Lung Cancer Res. 2018 Aug;7(4):450-463. doi: 10.21037/tlcr.2018.05.14. Transl Lung Cancer Res. 2018. PMID: 30225210 Free PMC article. Review.
EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C, Hirsch FR. Jiang T, et al. Among authors: zhou f, zhou c. Int J Cancer. 2019 May 15;144(10):2605-2612. doi: 10.1002/ijc.31962. Epub 2018 Dec 8. Int J Cancer. 2019. PMID: 30387880 Free article.
Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.
Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F, Ren S, Zhou C. Pan Y, et al. Among authors: zhou f, zhou c. Thorac Cancer. 2019 Apr;10(4):686-694. doi: 10.1111/1759-7714.12986. Epub 2019 Feb 22. Thorac Cancer. 2019. PMID: 30793872 Free PMC article.
Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer.
Zhang J, Zhou F, Qi H, Ni H, Hu Q, Zhou C, Li Y, Baburina I, Courtney J, Salamone SJ. Zhang J, et al. Among authors: zhou f, zhou c. Br J Clin Pharmacol. 2019 Oct;85(10):2292-2301. doi: 10.1111/bcp.13982. Epub 2019 Jun 14. Br J Clin Pharmacol. 2019. PMID: 31077432 Free PMC article.
10,053 results
You have reached the last available page of results. Please see the User Guide for more information.